Search academic texts

Information × Registration Number 0223U005804, 0122U000581 , R & D reports Title To study effects of COVID-19 on the course of recurrent and chronic bronchopulmonary diseases in children and work out ways for prevention of unfavorable consequences popup.stage_title Head Rechkina Olena O., Доктор медичних наук Registration Date 31-12-2023 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  The object of the study is 80 children who have suffered from COVID-19 and have a history of recurrent and chronic bronchopulmonary diseases. Aim – the purpose of the work is to develop an algorithm for managing children with recurrent and chronic bronchopulmonary diseases to prevent possible adverse consequences caused by COVID-19. Methods – clinical, questionnaire, mathematical, statistical. It was determined that the frequency of development of post-covid syndrome in children with recurrent and chronic bronchopulmonary diseases is 17.1%, regardless of the severity of the course of COVID-19. It was established that post-covid syndrome in children with recurrent and chronic bronchopulmonary diseases was manifested by cough in 12.8% of cases, general weakness in 10.0%, headache and a decrease in cognitive properties in 4.3% of patients. After the transfer of COVID-19 in children with bronchial asthma, an increase in the frequency of positive response to salbutamol from 6.7% to 15.5% during the broncholytic test was established. The average increase in FEV1 was 1.4 times higher (7.32 ± 1.67% versus 5.14 ± 1.24%). A significant decrease in the MOSH25 indicator was recorded in children after suffering from COVID-19 (70.72 ± 5.12 vs. 90.82 ± 9.94). The detected changes indicate the preservation of hyperreactivity at the level of small airways. A method of treatment of post-covid syndrome manifested by cough in children with bronchial asthma has been developed, the essence of which is the additional appointment to the basic treatment of the drug Ectoin in one single-dose container (2.5 ml) twice a day, using a nebulizer, for 10 days, which allows you to reduce the intensity of cough by 2.1 times and achieve the disappearance of cough in 33.3% of children. There were no side effects from the use of the drug. Sphere of application – pediatrics, pulmonology, allergology. Product Description popup.authors Kravtsova Oksana M. Promska Nataliia V Rechkina Olena O. Rudenko Sergii Mykolaiovych popup.nrat_date 2023-12-31 Close